The purchasing and marking up of expired drugs/patents and blocking of transition to generic status seem the obvious counterexamples here... https://hbr.org/20

The purchasing and marking up of expired drugs/patents and blocking of transition to generic status seem the obvious counterexamples here... https://hbr.org/2017/04/how-pharma-companies-game-the-system-to-keep-drugs-expensive https://hbr.org/2017/04/how-pharma-companies-game-the-system...